Docetexal plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study

2014 ◽  
Vol 37 (1-2) ◽  
pp. 24-28 ◽  
Author(s):  
Mei Wang ◽  
Meihong Wu ◽  
Wei Wang ◽  
Qingshui Wang ◽  
Yajie Wang
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Advanced Gastric Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals A Retrospective Study of Pegylated Liposomal Doxorubicin Combined with S-1 and Low-dose Oxaliplatin as First-Line Treatment for Advanced Gastric Cancer

2020 ◽  
Author(s):  
Jian Ma ◽  
Quanliang Yang ◽  
Yanzhi Bi ◽  
Min Xiao ◽  
Xiaoqian Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Advanced Gastric Cancer ◽  
Low Dose ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Drug Regimen ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Abstract Background: At present, the first-line treatment of advanced gastric cancer is oxaliplatin combined with fluorouracil (capecitabine or S-1). Is there a three-drug regimen in which the curative effect is higher than that of the two-drug regimen, but the side effects are not significantly increased? This retrospective study evaluated the efficacy and side effects of pegylated liposomal doxorubicin (PLD) combined with S-1 and low-dose oxaliplatin as first-line treatment for advanced gastric cancer.Methods: Advanced gastric cancer patients who received PLD combined with S-1 and low-dose oxaliplatin (D-SOX) or standard SOX as first-line chemotherapy from Jan 2015 to Dec 2018 were included in the study. Overall survival (OS), progression-free survival (PFS), response rate (RR), and safety were assessed. Results: A total of 52 patients were included in this study. There were 23 cases in D-SOX group and 29 cases in SOX group. The median PFS was 7.1 months (95% CI 5.66–8.54 months) in the SOX group and 9.1 months (95% CI 4.2–14.0 months) in the D-SOX group (P=0.036). The median OS was 12.5 months (95% CI 7.31–17.70 months) in the SOX group and 19.5 months (95% CI 16.23–22.7 months) in the D-SOX group (P=0.017). The incidence of treatment-related grade III-IV adverse events was no more than 10%. The incidence of neurotoxicity was significantly reduced in the D-SOX group.Conclusions: This study suggests that PLD combined with S-1 and low-dose oxaliplatin might be a safe and more effective treatment for advanced gastric cancer.

scholarly journals Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake

2018 ◽  
Vol Volume 11 ◽  
pp. 8301-8307 ◽  
Author(s):  
Hiroki Osumi ◽  
Daisuke Takahari ◽  
Keisho Chin ◽  
Mariko Ogura ◽  
Takashi Ichimura ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Oral Intake ◽  
Line Treatment ◽  
First Line ◽  
Massive Ascites ◽  
Modified Folfox6 ◽  
Inadequate Oral Intake ◽  
First Line Treatment

Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer

2019 ◽  
Vol 30 (3) ◽  
pp. 302-307 ◽  
Author(s):  
Wan-Cai Que ◽  
Yan-Fang Huang ◽  
Xiao-Yan Lin ◽  
Yan-Qin Lan ◽  
Xin-Yan Gao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Combination Chemotherapy ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer

Oncology ◽  
2011 ◽  
Vol 80 (5-6) ◽  
pp. 359-365 ◽  
Author(s):  
K. Amarantidis ◽  
N. Xenidis ◽  
L. Chelis ◽  
E. Chamalidou ◽  
P. Dimopoulos ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document